scholarly article | Q13442814 |
P356 | DOI | 10.1111/BJH.14322 |
P698 | PubMed publication ID | 27649938 |
P50 | author | James O Armitage | Q87934469 |
P2093 | author name string | Oliver Sartor | |
Charles L Bennett | |||
Joseph R Berger | |||
Dennis W Raisch | |||
Kenneth R Carson | |||
LeAnn B Norris | |||
Peter Georgantopoulos | |||
William J Hrushesky | |||
P2860 | cites work | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project | Q35701501 | ||
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
Progressive multifocal leukoencephalopathy in a patient with X-linked agammaglobulinemia | Q48031256 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
lymphocyte | Q715347 | ||
P304 | page(s) | 301-304 | |
P577 | publication date | 2016-09-21 | |
P1433 | published in | British Journal of Haematology | Q4970200 |
P1476 | title | Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. | |
P478 | volume | 180 |
Q48176410 | Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study. |
Q39010883 | Ibrutinib: A Review in Chronic Lymphocytic Leukaemia |
Q91283883 | Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) |
Q33891255 | Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) |
Q30235523 | Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency. |
Q47796704 | The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars |